{"id":"https://openalex.org/W3095832065","doi":"https://doi.org/10.1182/blood-2020-136158","title":"Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001","display_name":"Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3095832065","doi":"https://doi.org/10.1182/blood-2020-136158","mag":"3095832065"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-136158","doi":"https://doi.org/10.1182/blood-2020-136158","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-136158","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052659722","display_name":"Maria Lia Palomba","orcid":"https://orcid.org/0000-0001-5099-9156","observed_orcids":["https://orcid.org/0000-0001-5099-9156"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maria Lia Palomba","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010130956","display_name":"Leo I. Gordon","orcid":"https://orcid.org/0000-0003-1666-7064","observed_orcids":["https://orcid.org/0000-0003-1666-7064"]},"institutions":[{"id":"https://openalex.org/I111979921","display_name":"Northwestern University","ror":"https://ror.org/000e0be47","country_code":"US","type":"education","lineage":["https://openalex.org/I111979921"]},{"id":"https://openalex.org/I4390039227","display_name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","ror":"https://ror.org/02p4far57","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210147348","https://openalex.org/I4390039227"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leo I. Gordon","raw_affiliation_strings":["Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL","institution_ids":["https://openalex.org/I111979921","https://openalex.org/I4390039227"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005565037","display_name":"Tanya Siddiqi","orcid":"https://orcid.org/0000-0001-5292-8298","observed_orcids":["https://orcid.org/0000-0001-5292-8298"]},"institutions":[{"id":"https://openalex.org/I1301076528","display_name":"City Of Hope National Medical Center","ror":"https://ror.org/00w6g5w60","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1301076528"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tanya Siddiqi","raw_affiliation_strings":["City of Hope National Medical Center, Duarte, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"City of Hope National Medical Center, Duarte, CA","institution_ids":["https://openalex.org/I1301076528"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002103749","display_name":"Jeremy S. Abramson","orcid":"https://orcid.org/0000-0001-8467-9257","observed_orcids":["https://orcid.org/0000-0001-8467-9257"]},"institutions":[{"id":"https://openalex.org/I4210087915","display_name":"Massachusetts General Hospital","ror":"https://ror.org/002pd6e78","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210087915","https://openalex.org/I48633490"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeremy S. Abramson","raw_affiliation_strings":["Massachusetts General Hospital Cancer Center, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Massachusetts General Hospital Cancer Center, Boston, MA","institution_ids":["https://openalex.org/I4210087915"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000537427","display_name":"Manali Kirtikumar Kamdar","orcid":"https://orcid.org/0000-0002-1930-152X","observed_orcids":["https://orcid.org/0000-0002-1930-152X"]},"institutions":[{"id":"https://openalex.org/I4210134151","display_name":"University of Colorado Cancer Center","ror":"https://ror.org/04cqn7d42","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134151"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Manali Kamdar","raw_affiliation_strings":["University of Colorado Cancer Center, Aurora, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado Cancer Center, Aurora, CO","institution_ids":["https://openalex.org/I4210134151"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088179815","display_name":"Matthew Alexander Lunning","orcid":"https://orcid.org/0000-0002-2761-7612","observed_orcids":["https://orcid.org/0000-0002-2761-7612"]},"institutions":[{"id":"https://openalex.org/I59130452","display_name":"University of Nebraska Medical Center","ror":"https://ror.org/00thqtb16","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I59130452"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew A. Lunning","raw_affiliation_strings":["University of Nebraska Medical Center, Omaha, NE"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Nebraska Medical Center, Omaha, NE","institution_ids":["https://openalex.org/I59130452"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016684714","display_name":"David G. Maloney","orcid":"https://orcid.org/0000-0002-8477-6919","observed_orcids":["https://orcid.org/0000-0002-8477-6919"]},"institutions":[{"id":"https://openalex.org/I4210089486","display_name":"Fred Hutch Cancer Center","ror":"https://ror.org/007ps6h72","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I4210089486"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David G. Maloney","raw_affiliation_strings":["Fred Hutchinson Cancer Research Center, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fred Hutchinson Cancer Research Center, Seattle, WA","institution_ids":["https://openalex.org/I4210089486"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068715900","display_name":"Charalambos Babis Andreadis","orcid":"https://orcid.org/0000-0003-4681-6227","observed_orcids":["https://orcid.org/0000-0003-4681-6227"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]},{"id":"https://openalex.org/I4210167126","display_name":"UCSF Helen Diller Family Comprehensive Cancer Center","ror":"https://ror.org/05yndxy10","country_code":"US","type":"facility","lineage":["https://openalex.org/I180670191","https://openalex.org/I4210110664","https://openalex.org/I4210167126"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charalambos Andreadis","raw_affiliation_strings":["Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA","institution_ids":["https://openalex.org/I180670191","https://openalex.org/I4210167126"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016770040","display_name":"Jon E. Arnason","orcid":"https://orcid.org/0000-0001-9038-7277","observed_orcids":["https://orcid.org/0000-0001-9038-7277"]},"institutions":[{"id":"https://openalex.org/I1316535847","display_name":"Beth Israel Deaconess Medical Center","ror":"https://ror.org/04drvxt59","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1316535847"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jon E. Arnason","raw_affiliation_strings":["Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA","institution_ids":["https://openalex.org/I1316535847","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074766331","display_name":"Nilanjan Ghosh","orcid":"https://orcid.org/0000-0002-3848-6136","observed_orcids":["https://orcid.org/0000-0002-3848-6136","https://orcid.org/0000-0002-7217-243X"]},"institutions":[{"id":"https://openalex.org/I4210100342","display_name":"Levine Cancer Institute","ror":"https://ror.org/0174nh398","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334069289","https://openalex.org/I4210100342"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nilanjan Ghosh","raw_affiliation_strings":["Levine Cancer Institute, Atrium Health, Charlotte, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Levine Cancer Institute, Atrium Health, Charlotte, NC","institution_ids":["https://openalex.org/I4210100342"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030631799","display_name":"Amitkumar Mehta","orcid":"https://orcid.org/0000-0003-0537-4207","observed_orcids":["https://orcid.org/0000-0003-0537-4207"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amitkumar Mehta","raw_affiliation_strings":["University of Alabama at Birmingham, Birmingham, AL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Alabama at Birmingham, Birmingham, AL","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006999192","display_name":"Scott R. Solomon","orcid":"https://orcid.org/0000-0003-2061-8126","observed_orcids":["https://orcid.org/0000-0003-2061-8126"]},"institutions":[{"id":"https://openalex.org/I101890099","display_name":"Northside Hospital","ror":"https://ror.org/01g63ab19","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I101890099"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott R. Solomon","raw_affiliation_strings":["Immunotherapy Program, Northside Hospital Cancer Institute, Atlanta, GA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Immunotherapy Program, Northside Hospital Cancer Institute, Atlanta, GA","institution_ids":["https://openalex.org/I101890099"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050331636","display_name":"Thalia Andrea Farazi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I4405280080","display_name":"Juno Therapeutics (United States)","ror":"https://ror.org/02dq5dx40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thalia Farazi","raw_affiliation_strings":["Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA","institution_ids":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039487484","display_name":"Jacob Garcia","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I4405280080","display_name":"Juno Therapeutics (United States)","ror":"https://ror.org/02dq5dx40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jacob Garcia","raw_affiliation_strings":["Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA","institution_ids":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108654277","display_name":"Christine Dehner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]},{"id":"https://openalex.org/I4405280080","display_name":"Juno Therapeutics (United States)","ror":"https://ror.org/02dq5dx40","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christine Dehner","raw_affiliation_strings":["Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA","institution_ids":["https://openalex.org/I4210091812","https://openalex.org/I4405280080"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059141673","display_name":"Ken Ogasawara","orcid":"https://orcid.org/0000-0002-4264-8927","observed_orcids":["https://orcid.org/0000-0002-4264-8927"]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ken Ogasawara","raw_affiliation_strings":["Bristol-Myers Squibb Company, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Company, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Jie Gao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jie Gao","raw_affiliation_strings":["Bristol-Myers Squibb Company, Princeton, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb Company, Princeton, NJ","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100438316","display_name":"Michael L. Wang","orcid":"https://orcid.org/0000-0001-9748-5486","observed_orcids":["https://orcid.org/0000-0001-9748-5486"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Wang","raw_affiliation_strings":["Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":18,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":5.0353,"has_fulltext":false,"cited_by_count":67,"citation_normalized_percentile":{"value":0.96883615,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"136","issue":"Supplement 1","first_page":"10","last_page":"11"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mantle-cell-lymphoma","display_name":"mantle cell lymphoma","score":0.9340000152587891},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.9549999833106995},{"id":"https://openalex.org/keywords/lisocabtagene-maraleucel","display_name":"lisocabtagene maraleucel","score":0.9750000238418579},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.8360000252723694},{"id":"https://openalex.org/keywords/cd19","display_name":"CD19","score":0.871999979019165},{"id":"https://openalex.org/keywords/4-1bb","display_name":"4-1BB","score":0.9850000143051147},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6549999713897705},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.6359999775886536},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.9470000267028809},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.7919999957084656},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.7820000052452087},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6129999756813049},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8050000071525574},{"id":"https://openalex.org/keywords/lymphodepleting-chemotherapy","display_name":"lymphodepleting chemotherapy","score":0.8389999866485596},{"id":"https://openalex.org/keywords/bridging-therapy","display_name":"bridging therapy","score":0.5550000071525574},{"id":"https://openalex.org/keywords/tp53-mutation","display_name":"TP53 mutation","score":0.515999972820282},{"id":"https://openalex.org/keywords/complex-karyotype","display_name":"complex karyotype","score":0.652999997138977}],"concepts":[{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.8882068395614624},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6279046535491943},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5428687334060669},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.5244279503822327},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.483634352684021},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44824913144111633},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.10688680410385132},{"id":"https://openalex.org/C87355193","wikidata":"https://www.wikidata.org/wiki/Q411","display_name":"Astrobiology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-136158","doi":"https://doi.org/10.1182/blood-2020-136158","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-136158","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2954529696","https://openalex.org/W4389527245","https://openalex.org/W7162542774","https://openalex.org/W4380081053","https://openalex.org/W3095280492","https://openalex.org/W4407976286","https://openalex.org/W7204732048","https://openalex.org/W4386332213","https://openalex.org/W7128696688","https://openalex.org/W4389221804"],"abstract_inverted_index":{"Background:":[0],"Mantle":[1],"cell":[2,33,85],"lymphoma":[3,12],"(MCL)":[4],"is":[5,675],"an":[6,77,598,715,726,737,753,765,777,799,810,1122,1151,1168,1198],"aggressive":[7],"subtype":[8],"of":[9,49,55,92,116,127,155,175,258,261,267,275,285,484,592,645,659,667,718,729,740,802,813,1154,1171,1201],"B-cell":[10],"non-Hodgkin":[11],"(NHL).":[13],"Most":[14],"patients":[15,40,66,101,121,189,209,223,228,303,322,328,382,385,436,476,494,557,562,633,646],"with":[16,22,41,67,109,499,558,597,647,651,655],"MCL":[17,69,104,681],"relapse":[18],"after":[19,112],"first-line":[20],"immunochemotherapy,":[21],"poor":[23],"responses":[24],"to":[25,296,318,421,461,524,580],"salvage":[26],"therapy.":[27,117,300,320,326],"Chimeric":[28],"antigen":[29],"receptor":[30],"(CAR)":[31],"T":[32,84,97,137,145],"therapy":[34,148],"has":[35],"shown":[36],"clinical":[37,671],"efficacy":[38],"in":[39,65,380,492,679,988,1226,1243,1259,1271],"relapsed/refractory":[42],"(R/R)":[43],"NHL.":[44],"We":[45],"report":[46],"the":[47,50,56,207,213,259,319,555,576,604,680],"results":[48],"dose-finding":[51],"and":[52,94,153,162,181,193,221,245,271,291,336,348,424,430,464,470,507,538,616,663,669,760,771,789,1029],"dose-expansion":[53],"parts":[54],"ongoing":[57,599,676],"phase":[58,642],"1":[59,126,403,508,584,643],"TRANSCEND":[60],"NHL":[61],"001":[62],"study":[63,376,644],"(NCT02631044)":[64],"R/R":[68,110,648],"(MCL":[70],"cohort)":[71],"who":[72,210,305,571],"received":[73,122,196,211,281,307,324,478],"lisocabtagene":[74],"maraleucel":[75],"(liso-cel),":[76],"investigational,":[78],"CD19-directed,":[79],"defined":[80],"composition,":[81],"4-1BB":[82],"CAR":[83],"product":[86,260],"administered":[87],"at":[88,125,357,364,375,407,443,634,637,677],"equal":[89],"target":[90],"doses":[91],"CD8+":[93],"CD4+":[95],"CAR+":[96,136,144],"cells.":[98],"Methods:":[99],"Eligible":[100],"had":[102,190,195,230,235,241,248,253,280,306,330,339,397,438,503,510,563,602],"confirmed":[103],"(cyclin":[105],"D1":[106],"expression,":[107],"t[11;14])":[108],"disease":[111],"\u22651":[113],"prior":[114,288,299,309],"line":[115],"After":[118],"lymphodepleting":[119,156,265],"chemotherapy,":[120],"liso-cel":[123,197,525,652],"infusion":[124],"2":[128,493],"dose":[129,517],"levels":[130],"(DLs):":[131],"DL1":[132,365,615],"(50":[133],"\u00d7":[134,142],"106":[135,143],"cells)":[138],"or":[139,414,453,601,720,731,742,804,815,1156,1173,1203],"DL2":[140,358,513,635,678],"(100":[141],"cells).":[146],"Bridging":[147],"was":[149,217,354,426,466,514,583,610,630,653],"allowed":[150],"between":[151],"leukapheresis":[152,192],"initiation":[154],"chemotherapy.":[157],"Primary":[158],"endpoints":[159,168],"were":[160,225,294,316,410,456,595],"safety":[161],"objective":[163],"response":[164,171,565,600],"rate":[165],"(ORR).":[166],"Secondary":[167],"included":[169],"complete":[170],"(CR)":[172],"rate,":[173],"duration":[174,609],"response,":[176],"progression-free":[177],"survival,":[178,180],"overall":[179],"pharmacokinetics":[182],"(PK).":[183],"Results:":[184],"At":[185,587],"data":[186,588],"cutoff,":[187,589],"41":[188],"undergone":[191],"32":[194,208,520],"(DL1,":[198,544],"n":[199,203,388,393,529,534,545,550],"=":[200,204,360,367,389,394,530,535,546,551],"6;":[201],"DL2,":[202,392,444,533,549],"26).":[205],"Among":[206,554],"liso-cel,":[212],"median":[214,255,272,283,577,627],"(range)":[215,256,284,419,459,578,607],"age":[216],"67":[218],"(36\u201280)":[219],"years":[220],"27":[222,337,522,593],"(84%)":[224,338],"male.":[226],"Twelve":[227],"(37.5%)":[229],"blastoid":[231,559],"morphology,":[232,560],"23":[233],"(72%)":[234,293],"documented":[236],"Ki67":[237],"\u226530%,":[238],"7":[239,569],"(22%)":[240],"a":[242,249,254,282,308,542,564,573,656,959,1215,1231,1248],"TP53":[243],"mutation,":[244],"11":[246,314,381],"(34%)":[247,315],"complex":[250],"karyotype.":[251],"Patients":[252,279],"sum":[257],"perpendicular":[262],"diameters":[263],"before":[264],"chemotherapy":[266],"28.7":[268],"(0-209.6)":[269],"cm2":[270],"lactate":[273],"dehydrogenase":[274],"251.5":[276],"(117-811)":[277],"U/L.":[278],"3":[286,413,446,448,471],"(1-7)":[287],"systemic":[289],"therapies,":[290],"most":[292],"refractory":[295,317],"their":[297],"last":[298],"Of":[301,519],"28":[302],"(87.5%)":[304],"Bruton":[310],"tyrosine":[311],"kinase":[312],"inhibitor,":[313],"Seventeen":[321],"(53%)":[323],"bridging":[325],"Eighteen":[327],"(56%)":[329],"serious":[331],"treatment-emergent":[332],"adverse":[333],"events":[334,440],"(TEAEs),":[335],"grade":[340,371,404,412,447,451,660],"\u22653":[341,352,372,661],"TEAEs,":[342],"primarily":[343],"neutropenia":[344],"(41%),":[345],"anemia":[346],"(34%),":[347],"thrombocytopenia":[349,353],"(31%).":[350],"Grade":[351,488],"more":[355],"frequent":[356],"(n":[359,366],"9/26":[361],"[35%])":[362],"than":[363,636],"1/6":[368],"[17%]).":[369],"Prolonged":[370],"cytopenias":[373],"(present":[374],"Day":[377],"29)":[378],"occurred":[379,491],"(34%).":[383],"Sixteen":[384],"(50%;":[386],"DL1,":[387,528],"2/6":[390,547],"[33%];":[391,548],"14/26":[395],"[54%])":[396],"cytokine":[398],"release":[399],"syndrome":[400,506],"(CRS),":[401],"including":[402,445,568],"4":[405,431,452],"event":[406],"DL2.":[408,621],"There":[409],"no":[411,1006,1008],"5":[415,454,489],"CRS":[416,422,485,662],"events.":[417],"Median":[418,458,606],"time":[420,460,579],"onset":[423,463,666],"resolution":[425,465],"6":[427],"(2\u201210)":[428],"days":[429,469],"(2\u20129)":[432],"days,":[433,473],"respectively.":[434,474],"Nine":[435],"(28%)":[437],"neurological":[439],"(NEs),":[441],"all":[442],"NEs.":[449,487],"No":[450,710],"NEs":[455],"reported.":[457],"NE":[462],"8":[467],"(2\u201225)":[468],"(1\u201251)":[472],"Ten":[475],"(31%)":[477],"tocilizumab":[479],"and/or":[480,486],"corticosteroids":[481],"for":[482,516,614,620],"treatment":[483,650],"TEAEs":[490],"(at":[495],"DL2):":[496],"one":[497],"patient":[498,509],"high":[500],"tumor":[501,504],"burden":[502],"lysis":[505],"cryptococcal":[511],"meningoencephalitis.":[512],"selected":[515],"expansion.":[518],"patients,":[521],"responded":[523],"(ORR,":[526,566],"84%:":[527],"4/6":[531],"[67%];":[532],"23/26":[536],"[88%]),":[537],"19":[539],"(59%)":[540],"achieved":[541,572],"CR":[543,582],"17/26":[552],"[65%]).":[553],"12":[556],"9":[561],"75%),":[567],"(58%)":[570],"CR.":[574],"Overall,":[575],"first":[581],"(1-6)":[585],"month.":[586],"20":[590],"(74%)":[591],"responders":[594],"censored":[596],"completed":[603],"study.":[605],"follow-up":[608],"10.9":[611],"(1.2-24.8)":[612],"months":[613,619],"3.1":[617],"(0.4-23.0)":[618],"Preliminary":[622],"PK":[623],"analysis":[624],"indicated":[625],"that":[626],"maximum":[628],"expansion":[629],"higher":[631],"among":[632],"DL1.":[638],"Conclusions:":[639],"In":[640],"this":[641],"MCL,":[649],"associated":[654],"low":[657],"incidence":[658],"NEs,":[664],"late":[665],"CRS/NEs,":[668],"promising":[670],"activity.":[672],"Dose":[673],"confirmation":[674],"cohort.":[682],"Disclosures":[683],"Palomba:":[684],"Pharmacyclics:":[685,908,972],"Honoraria;":[686,688,690,692,694,893,927,930,933,936,939,946,949,954,968,971,974,977,981,991,1015,1018],"Juno:":[687,698,1064],"Celgene:":[689,734,1019],"Merck:":[691,871,1040,1137],"Novartis:":[693,876,937,975,1031],"Regeneron:":[695],"Research":[696,699,702,791,920,923,942,964,1010,1022,1032,1035,1038,1041,1071,1073,1087,1097,1101,1108,1116,1126,1132,1135,1138,1141,1144,1159,1176,1182,1186,1189,1192,1206,1211],"Funding;":[697,700,792,921,924,943,965,1011,1033,1036,1039,1042,1074,1088,1098,1109,1133,1136,1139,1142,1145,1183,1187,1190,1193],"Genentech:":[701,1016],"Funding.":[703,1023,1212],"Gordon:Zylem":[704],"Biosciences:":[705],"Patents":[706,996,999],"&":[707,997],"Royalties:":[708,998],"Patents,":[709],"Royalties.":[711],"Siddiqi:Juno:":[712],"Membership":[713,724,735,797,808,1149,1166,1196],"on":[714,725,736,798,809,1150,1167,1197],"entity's":[716,727,738,800,811,1152,1169,1199],"Board":[717,728,739,801,812,1153,1170,1200],"Directors":[719,730,741,803,814,1155,1172,1202],"advisory":[721,732,743,805,816,1157,1174,1204],"committees;":[722,733,744,806],"Kite:":[723,934],"BeiGene:":[745,761,790,890],"Other:":[746,794,820,826,831,837,842,847,852,857,862,867,1025,1044,1048,1051,1055,1058,1070],"DMC":[747],"member;":[748],"Juno":[749,780,824,992,1180],"Therapeutics,":[750,781,786,1214,1230,1247],"Pharmacyclics":[751,763,775,1120],"LLC,":[752,764,776,1121],"AbbVie":[754,766,778,1123],"Company,":[755,767,779],"AstraZeneca,":[756,784],"Celgene,":[757,787],"Kite":[758],"Pharma,":[759,783],"Consultancy;":[762,901,903,905,907,911,914,951,1063,1083],"Seattle":[768,880,1053,1163],"Genetics,":[769],"Janssen,":[770],"AstraZeneca:":[772,793,892,906,947,1093],"Speakers":[773,898,1077,1080,1091,1094,1103,1112,1118,1128,1161,1178,1208],"Bureau;":[774,899,1078,1081,1092,1095,1104,1113,1119,1162,1179,1209],"KITE":[782],"TG":[785,940,1105,1146],"Oncternal,":[788],"Travel/accommodations/expenses;":[795],"Astrazenca:":[796],"PCYC:":[807],"committees.":[817],"Abramson:Celgene:":[818],"Honoraria,":[819,919,963,995,1021],"Scientific":[821,827,832,838,843,848,853,858,863,868],"Advisory":[822,828,833,839,844,849,854,859,864,869],"Board;":[823,829,834,840,845,850,855,860,865,870],"Therapeutics:":[825,888,913,941,993,1106,1147],"AbbVie:":[830,1079],"EMD":[835],"Serono:":[836],"Genentech/Roche:":[841],"Janssen:":[846,928,1114],"Karyopharm:":[851,900,931,1057,1082],"Gilead:":[856,925],"Verastem:":[861,944],"Bayer:":[866],"Other;":[872,875,877,879,882,884,886,889,891],"KIte":[873],"Pharma:":[874],"Amgen:":[878,969,1037],"Genetics:":[881,897,1054,1164],"Allogene:":[883],"Morphosys:":[885],"C4":[887],"Incyte:":[894,1060,1194],"Honoraria.":[895,957],"Kamdar:Seattle":[896],"BMS:":[902],"Abbvie:":[904],"Consultancy.":[909,1065],"Lunning:Acrotech:":[910],"ADC":[912],"Bristol":[915],"Meyers":[916],"Squibb:":[917,1085,1111,1222,1255,1263,1267],"Consultancy,":[918,926,929,932,935,938,945,948,953,956,962,967,970,973,976,980,984,994,1014,1017,1020,1069,1076,1086,1090,1100,1107,1115,1125,1148,1165,1195],"Curis:":[922],"Legend:":[950],"Beigene:":[952],"Aeratech:":[955],"Maloney:Kite,":[958],"Gilead":[960,978],"Company:":[961,1124,1218,1234,1239,1251],"MorphoSys:":[966],"Sciences:":[979],"A2":[982],"Biotherapeutics:":[983],"Current":[985,1219,1223,1235,1240,1252,1256,1264,1268],"equity":[986,1224,1241,1257,1269],"holder":[987,1225,1242,1258,1270],"publicly-traded":[989,1227,1244,1260],"company,":[990],"are":[1000],"pending,":[1001],"but":[1002],"not":[1003],"issued,":[1004],"licensed,":[1005],"royalties,":[1007],"licensees.,":[1009],"Bioline":[1012],"Rx:":[1013],"Andreadis:Genentech:":[1024],"Spouse":[1026],"Employee":[1027],"(salary":[1028],"stock);":[1030],"Celgene/Juno:":[1034],"Gilead/Kite:":[1043],"Advisor;":[1045,1049,1052,1056,1059],"Jazz":[1046],"Pharmaceuticals:":[1047,1131],"Astellas:":[1050],"Other.":[1061],"Arnason:Regeneron:":[1062],"Ghosh:Forty":[1066],"Seven":[1067],"Inc:":[1068],"Bureau,":[1072],"Genmab:":[1075],"Juno/Celgene/Bristol-Myers":[1084],"Kite/Gilead:":[1089,1134],"Roche/Genentech:":[1096],"SGN:":[1099],"Funding,":[1102,1117,1127,1160,1177,1207],"Celgene/Bristol-Myers":[1110],"Bureau.":[1129],"Mehta:Innate":[1130],"Gelgene/BMS:":[1140],"Oncotartis:":[1143],"committees,":[1158,1175,1205],"Parmaceuticals/BMS:":[1181],"fortyseven":[1184],"Inc/Gilead:":[1185],"Takeda:":[1188],"Roche-Genentech:":[1191],"Affimed:":[1210],"Farazi:Juno":[1213],"Bristol-Myers":[1216,1221,1232,1237,1249,1254,1266],"Squibb":[1217,1233,1238,1250],"Employment;":[1220,1236,1253,1265],"company.":[1228,1245,1261],"Garcia:Juno":[1229],"Dehner:Juno":[1246],"Ogasawara:Bristol-Myers":[1262],"publicly":[1272]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":17},{"year":2022,"cited_by_count":21},{"year":2021,"cited_by_count":19}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2020-11-09T00:00:00"}